Prescient Therapeutics is a clinical stage oncology company developing novel drugs that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. This highly promising compound is the focus of three PTX clinical trials. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center/Albert Einstein College of Medicine in New York and the Moffitt Cancer Center and Research Institute in Tampa, Florida. A Phase 1b/2 trial of PTX-200 in combination with current standard of care carboplatin is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at Moffitt Cancer Center. In addition, a Phase 1b/2 trial evaluating PTX-200 incombination with citarabine in acute myeloid leukemia is scheduled to begin accrual in mid-2016.

Prescient’s second novel drug candidate, PTX-100, is a first in class drug that kills cancer cells by blocking geranylgeranyl ransferase-1 (GGT-1), a protein required for the cancer-causing activity of Ral and Rho, that are in turn required for the cancer-causing protein Ras. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors.  Prescient expects to commence Phase 1b/2 clinical trials in breast cancer and multiple myeloma in Q4 2016. At the same time, Prescient plans to develop its novel p27 cancer biomarker as a companion diagnostic that will potentially identify those patients that are most likely to respond to PTX-100 therapy.

Prescient has licensed access to its Co-X-Gene™ platform technology to French biotechnology company Transgene for use in two immunotherapeutic products.